Citations

Clear

1053 citation(s) found for "Andre, F".

Peer Review Certifies Quality and Innovation in Clinical Pharmacology & Therapeutics
Waldman, Scott A. , Waldman, Scott A , Terzic, André

Mayo Clinic

Clinical Pharmacology & Therapeutics | August 7, 2017 | Volume: 102 | Issue: 3 | Pages: 373-377

10.1002/cpt.763 | PMID 28782825 Get It

Clinical Pharmacology & Therapeutics (CPT) is an established voice of the discipline, a trusted source of new knowledge showcasing discovery, translation, and application of novel therapeutic paradigms to advance the management of patients and populations. Identifying, evaluating, prioritizing, and disseminating the best science along the discovery–development–regulatory–utilization continuum are responsibilities shared through peer review. To enhance the uniformity of this essential component of quality assurance and innovation, and maximize the value of the journal and its contents to authors, reviewers, and the readership, we review key concepts concerning peer review as it specifically relates to CPT.
Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis
Alberts, Rudi , Vries, Elisabeth M. G. de, Goode, Elizabeth C. , Jiang, Xiaojun , Sampaziotis, Fotis , Rombouts, Krista , Böttcher, Katrin , Folseraas, Trine , Weismüller, Tobias J. , Alexander, Graeme, Alvaro, Domenico , Bergquist, Annika , Björkström, Niklas K. , Beuers, Ulrich , Boberg, Kirsten Muri , Bowlus, Christopher L. , Bragazzi, Maria Consiglia , Chazouillères, Olivier , Cheung, Angela , Dalekos, Georgios, Eaton, John E. , Eksteen, Bertus , Ellinghaus, David , Färkkilâ, Martti , Festen, Eleonora A. , Floreani, Annarosa , Franceschet, I., Gotthardt, Daniel , Hoek, Bart van , Holm, Kristian , Hov, Johannes R. , Imhann, Floris , Juran, Brian D., Lenzen, Henrike , Marschall, Hanns–Ulrich , Marzioni, Marco , Melum, Espen , Milkiewicz, Piotr , Müller, Tobias , Parés, Albert , Rupp, Christian , Rust, Christian, Sandford, Richard , Schrumpf, Erik, Silverberg, Mark S. , Srivastava, Brijesh, Sterneck, Martina , Teufel, Andreas , Vallier, Ludovic , Verheij, Joanne , Vila, Arnau Vich , Vries, Boudewijn de, Zachou, Kalliopi , Chapman, Roger W. , Manns, Michael P. , Rushbrook, Simon, Anderson, Carl A. , Karlsen, Tom H. , Ponsioen, Cyriel Y. , Weersma, Rinse K. , Eaton, John, Lazaridis, Konstantinos N. , Ellinghaus, David , Bowlus, Christopher L , Marzioni, Marco , Mason, Andrew L. , Wang, Weiwei , Bjornsson, Einar Stefan , Carbone, Marco , Dalekos, Georgios, Hirschfield, Gideon M. , Hohenester, Simon D. , Invernizzi, Pietro , Lieb, Wolfgang , Liu, Jimmy Z. , Schramm, Christoph , Schreiber, Stefan , Pinzani, Massimo , Franke, André , Bergquist, Annika , Milkiewicz, Piotr , Alvaro, Domenico , Hov, Johannes R , Anderson, Carl A

Mayo Clinic

Gut | August 4, 2017 | Volume: 67 | Issue: 8 | Pages: 1517-1524

10.1136/gutjnl-2016-313598 | PMID 28779025 Get It

Objective Primary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications. Design We collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportional hazards models, we identified genetic variants associated with binary and time-to-event PSC subphenotypes. Results We identified genetic variant rs853974 to be associated with liver transplant-free survival (p=6.07×10–9). Kaplan-Meier survival analysis showed a 50.9% (95% CI 41.5% to 59.5%) transplant-free survival for homozygous AA allele carriers of rs853974 compared with 72.8% (95% CI 69.6% to 75.7%) for GG carriers at 10 years after PSC diagnosis. For the candidate gene in the region, RSPO3, we demonstrated expression in key liver-resident effector cells, such as human and murine cholangiocytes and human hepatic stellate cells. Conclusion We present a large international PSC cohort, and report genetic loci associated with PSC disease progression. For liver transplant-free survival, we identified a genome-wide significant signal and demonstrated expression of the candidate gene RSPO3 in key liver-resident effector cells. This warrants further assessments of the role of this potential key PSC modifier gene.
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasiv
Hendry, Shona , Salgado, Roberto , Gevaert, Thomas, Russell, Prudence A. , John, Tom, Thapa, Bibhusal , Estrada, Mónica V. , González-Ericsson, Paula I. , Solomon, Benjamin , Solinas, Cinzia , Eynden, Gert G. G. M. Van den, Preusser, Matthias , Hainfellner, Johannes A. , Pruneri, Giancarlo , Vingiani, Andrea , Demaria, Sandra , Symmans, Fraser, Nucíforo, Paolo , Comerma, Laura , Thompson, E. Aubrey , Kim, Seong-Rim , Schnitt, Stuart J. , Colpaert, Cécile , Scherer, Stefan, Viale, Giuseppe , Sirtaine, Nicolas , Penault‐Llorca, Frédérique, Sugie, Tomohagu, Fineberg, Susan , Paik, Soonmyung , Richardson, Andrea L., Wang, Yihong , Chmielik, Ewa , Brock, Jane B. , Johnson, Douglas B. , Wienert, Stephan, Bossuyt, Veerle , Michiels, Stefan , Ternès, Nils, Burchardi, Nicole, Klauschen, Frederick , Watson, Peter H. , Nelson, Brad H. , O’Toole, Sandra A., Larsimont, Denis , Wind, Roland de, Curigliano, Giuseppe , André, Fabrice , Vijver, Marc J. van de , Rojo, Federico , Floris, Giuseppe , Bedri, Shahinaz , Sparano, Joseph A. , Rimm, David L. , Kos, Zuzana , Hewitt, Stephen M. , Farshid, Gelareh , Loibl, Sibylle , Allison, Kimberly H. , Adams, Sylvia , Willard‐Gallo, Karen , Gandhi, Leena , Moreira, André L. , Hirsch, Fred R. , Dieci, Maria Vittoria , Urbanowicz, María, Brčić, Iva , Korski, Konstanty, Gaire, Fabien, Koeppen, Hartmut , Lo, Amy, Rebelatto, Marlon C., Steele, Keith E. , Zha, Jiping, Emancipator, Kenneth , Juco, Jonathan, Loi, Sherene , Fox, Stephen B. , Symmans, W. Fraser , John, Thomas , Wang, Yihong , Gonzalez-Ericsson, Paula I , Curigliano, Giuseppe , Sparano, Joseph A , Nelson, Brad H , Preusser, Matthias , André, Fabrice , Symmans, W Fraser , Loi, Sherene , John, Tom, Christie, Michael , Van de Vijver, Koen , Sanders, Melinda E. , Allory, Yves , Lakhani, Sunil R. , Sotiriou, Christos P. , Ignatiadis, Michail , Badve, Sunil , Pierce, Robert Hamilton , Srinivasan, Ashok , Richardson, Andrea L. , Balko, Justin M. , Luen, Stephen James , Savas, Peter Stephen , Criscitiello, Carmen , Lacroix‐Triki, Magali , Nielsen, Torsten O. , Singh, Baljit , Tung, Nadine , Horlings, Hugo , Lo, Amy, Giltnane, Jennifer Margaret , Denkert, Carsten , Reis‐Filho, Jorge S. , Pruneri, Giancarlo , Rimm, David , Dieci, Maria Vittoria , Nuciforo, Paolo , Solomon, Benjamin J

Mayo Clinic

Advances in Anatomic Pathology | August 2, 2017 | Volume: 24 | Issue: 5 | Pages: 235-251

10.1097/pap.0000000000000162 | PMID 28777142 Get It

Assessment of tumor-infiltrating lymphocytes (TILs) in histopathologic specimens can provide important prognostic information in diverse solid tumor types, and may also be of value in predicting response to treatments. However, implementation as a routine clinical biomarker has not yet been achieved. As successful use of immune checkpoint inhibitors and other forms of immunotherapy become a clinical reality, the need for widely applicable, accessible, and reliable immunooncology biomarkers is clear. In part 1 of this review we briefly discuss the host immune response to tumors and different approaches to TIL assessment. We propose a standardized methodology to assess TILs in solid tumors on hematoxylin and eosin sections, in both primary and metastatic settings, based on the International Immuno-Oncology Biomarker Working Group guidelines for TIL assessment in invasive breast carcinoma. A review of the literature regarding the value of TIL assessment in different solid tumor types follows in part 2. The method we propose is reproducible, affordable, easily applied, and has demonstrated prognostic and predictive significance in invasive breast carcinoma. This standardized methodology may be used as a reference against which other methods are compared, and should be evaluated for clinical validity and utility. Standardization of TIL assessment will help to improve consistency and reproducibility in this field, enrich both the quality and quantity of comparable evidence, and help to thoroughly evaluate the utility of TILs assessment in this era of immunotherapy.
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinoma
Hendry, Shona , Salgado, Roberto , Gevaert, Thomas, Russell, Prudence A. , John, Tom, Thapa, Bibhusal , Estrada, Mónica V. , González-Ericsson, Paula I. , Sanders, Melinda, Solomon, Benjamin , Solinas, Cinzia , Eynden, Gert G. G. M. Van den, Preusser, Matthias , Hainfellner, Johannes A. , Pruneri, Giancarlo , Vingiani, Andrea , Demaria, Sandra , Symmans, Fraser, Nucíforo, Paolo , Comerma, Laura , Thompson, E. Aubrey , Kim, Seong-Rim , Schnitt, Stuart J. , Colpaert, Cécile , Scherer, Stefan, Viale, Giuseppe , Sirtaine, Nicolas , Sugie, Tomohagu, Fineberg, Susan , Paik, Soonmyung , Richardson, Andrea L., Wang, Yihong , Chmielik, Ewa , Brock, Jane, Johnson, Douglas B. , Wienert, Stephan, Bossuyt, Veerle , Michiels, Stefan , Ternès, Nils, Burchardi, Nicole, Savas, Peter, Klauschen, Frederick , Watson, Peter H. , Nelson, Brad H. , O’Toole, Sandra A., Larsimont, Denis , Wind, Roland de, Curigliano, Giuseppe , André, Fabrice , Vijver, Marc J. van de , Rojo, Federico , Floris, Giuseppe , Bedri, Shahinaz , Sparano, Joseph A. , Rimm, David L. , Kos, Zuzana , Hewitt, Stephen M. , Farshid, Gelareh , Loibl, Sibylle , Allison, Kimberly H. , Adams, Sylvia , Willard‐Gallo, Karen , Gandhi, Leena , Hirsch, Fred R. , Dieci, Maria Vittoria , Urbanowicz, María, Brčić, Iva , Korski, Konstanty, Gaire, Fabien, Koeppen, Hartmut , Lo, Amy, Rebelatto, Marlon C., Steele, Keith E. , Zha, Jiping, Emancipator, Kenneth , Juco, Jonathan, Loi, Sherene , Fox, Stephen B. , Symmans, W. Fraser , John, Thomas , Wang, Yihong , Gonzalez-Ericsson, Paula I , Curigliano, Giuseppe , Sparano, Joseph A , Nelson, Brad H , Preusser, Matthias , André, Fabrice , Symmans, W Fraser , Loi, Sherene , John, Tom, Christie, Michael , Van de Vijver, Koen , Allory, Yves , Lakhani, Sunil R. , Sotiriou, Christos P. , Ignatiadis, Michail , Badve, Sunil , Pierce, Robert Hamilton , Penault-Llorca, Frederique Madeleine , Srinivasan, Ashok , Richardson, Andrea L. , Balko, Justin M. , Luen, Stephen James , Savas, Peter Stephen , Criscitiello, Carmen , Lacroix‐Triki, Magali , Nielsen, Torsten O. , Singh, Baljit , Tung, Nadine , Horlings, Hugo , Moreira, Andre M. , Lo, Amy, Giltnane, Jennifer Margaret , Denkert, Carsten , Reis‐Filho, Jorge S. , Pruneri, Giancarlo , Rimm, David , Dieci, Maria Vittoria , Nuciforo, Paolo , Solomon, Benjamin J

Mayo Clinic

Advances in Anatomic Pathology | August 2, 2017 | Volume: 24 | Issue: 6 | Pages: 311-335

10.1097/pap.0000000000000161 | PMID 28777143 Get It

Assessment of the immune response to tumors is growing in importance as the prognostic implications of this response are increasingly recognized, and as immunotherapies are evaluated and implemented in different tumor types. However, many different approaches can be used to assess and describe the immune response, which limits efforts at implementation as a routine clinical biomarker. In part 1 of this review, we have proposed a standardized methodology to assess tumor-infiltrating lymphocytes (TILs) in solid tumors, based on the International Immuno-Oncology Biomarkers Working Group guidelines for invasive breast carcinoma. In part 2 of this review, we discuss the available evidence for the prognostic and predictive value of TILs in common solid tumors, including carcinomas of the lung, gastrointestinal tract, genitourinary system, gynecologic system, and head and neck, as well as primary brain tumors, mesothelioma and melanoma. The particularities and different emphases in TIL assessment in different tumor types are discussed. The standardized methodology we propose can be adapted to different tumor types and may be used as a standard against which other approaches can be compared. Standardization of TIL assessment will help clinicians, researchers and pathologists to conclusively evaluate the utility of this simple biomarker in the current era of immunotherapy.
Abstract 5930: Osteoblasts protect AML cells from cytarabine-induced death
Sterner, Rosalie M. , Dudakovic, Amel , Wijnen, André J. van , van Wijnen, Andre J , Kremer, Kimberly N. , Westendorf, Jennifer J. , Hedin, Karen E.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 5930-5930

10.1158/1538-7445.am2017-5930 Get It

Abstract The hematological malignancy acute myeloid leukemia (AML) interacts closely with osteoblasts within the protective bone marrow microenvironment. The bone marrow microenvironment protects tumor cells from chemotherapies, which can prevent sufficient eradication of tumor cells. To study the role of osteoblasts in the bone marrow microenvironment, our lab utilized a co-culture model of osteoblasts (MC3T3 osteoblast cell line) and acute myelogenous leukemia cells (KG1a AML cell line or AML patient samples from bone marrow aspirates). Osteoblasts were cultured with AML cells, or AML cells were cultured alone; AML cells were challenged with the standard chemotherapeutic agent cytarabine (Ara-C) at doses of 0µM, 0.1µM, 0.5µM, 1µM, 5µM, or 10µM in the presence or absence of osteoblasts; and AML cells were assayed by flow cytometry to assess cell death via annexin-V staining. Our lab has previously found that differentiating osteoblasts protect AML cells from an apoptosis inducing agent naturally present in the bone marrow. We now show that osteoblasts are also capable of protecting AML cells from the standard chemotherapeutic cytarabine. In addition, we have found that treatment of osteoblasts with the histone deacetylase inhibitor (HDACi) suberoylanilide hydroxamic acid (SAHA) prevents these treated osteoblasts from protecting AML cells from cytarabine treatment, which is consistent with our lab’s previous findings that HDACi treatment inhibits protection of AML cells from an apoptosis inducing agent naturally present in the bone marrow. We have preliminary data that indicates that TAZS89A over-expression, a constitutively active form of TAZ, which is a transcriptional modulator that regulates osteoblast differentiation, may be sufficient to inhibit osteoblast mediated protection of AML cells from cytarabine. This finding would be consistent with the HDACi manipulated Nherf1-protein phosphatase 1α-TAZ signaling pathway that we have previously found to be sufficient to inhibit protection of AML cells from an apoptosis inducing agent naturally present in the bone marrow. Overall, these studies have delivered insights into the role of osteoblasts in protecting AML cells from chemotherapy in the bone marrow microenvironment and begun the characterization of mechanisms and targets responsible for the protective effects of osteoblasts. Manipulating differentiating osteoblasts within the bone marrow microenvironment therapeutically could aid in more complete destruction of the tumor cell burden and improve patient survival. Citation Format: Rosalie M. Sterner, Kimberly N. Kremer, Amel Dudakovic, Jennifer J. Westendorf, Andre J. van Wijnen, Karen E. Hedin. Osteoblasts protect AML cells from cytarabine-induced death [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5930. doi:10.1158/1538-7445.AM2017-5930
Serum Soluble Epidermal Growth Factor Receptor Concentrations Decrease in Postmenopausal Metastatic Breast Cancer Patients Treated with Letrozole
Lafky, Jacqueline M., Cora, Elsa M., Perez, Edith A. , Maihle, Nita J. , Baron, Andre T. , Hillman, David W. , Suman, Vera J. , Ingle, James N.

Mayo Clinic

Cancer Research | July 21, 2017 | Volume: 65 | Issue: 8 | Pages: 3059-3062

10.1158/0008-5472.can-05-0067 | PMID 15833834 Get It

Abstract Previous studies have implicated estrogen as a regulator of epidermal growth factor receptor (EGFR) expression in breast tumors. We therefore speculated that estrogen might modulate serologic soluble EGFR (sEGFR) concentrations in breast cancer patients. Accordingly, we measured serum sEGFR concentrations in postmenopausal women with metastatic breast cancer (MBC) treated with letrozole, an aromatase inhibitor that blocks estrogen synthesis. Serum specimens were obtained prior to and following 1 and 3 months of letrozole therapy. We report that sEGFR concentrations do not differ between MBC patients prior to letrozole treatment and age- and postmenopause-matched healthy women (P = 0.468). In contrast, however, sEGFR concentrations decreased significantly in 76% of MBC patients after both 1 month (P = 0.006) and 3 months (P = 0.003) of letrozole therapy versus pretreatment concentrations. Within the limitations of this study, we found no evidence for an association between pretreatment sEGFR concentrations or decreased treatment sEGFR concentrations and either progression-free or overall survival. Nonetheless, we conclude that future prospective studies are warranted to determine if baseline and/or longitudinal serum sEGFR concentrations may be useful for predicting disease progression and survival, and/or for monitoring responsiveness to aromatase inhibitors or other endocrine therapies in breast cancer patients.
Local Cellular Responses to Titanium Dioxide from Orthopedic Implants
Yao, Jie , Lewallen, Eric A. , Trousdale, William H. , Xu, Wei , Thaler, Roman , Salib, Christopher G. , Reina, Nicolas , Lewallen, David G. , Wijnen, André J. van , Yao, Jie J, Abdel, Matthew P. , van Wijnen, Andre J

Mayo Clinic

BioResearch Open Access | July 21, 2017 | Volume: 6 | Issue: 1 | Pages: 94-103

10.1089/biores.2017.0017 | PMID 29034133 Get It

Affairs of the Heart: Innovation in Cardiovascular Research and Development
Honig, P K, Terzic, André

Mayo Clinic

Clinical Pharmacology & Therapeutics | July 18, 2017 | Volume: 102 | Issue: 2 | Pages: 162-168

10.1002/cpt.737 | PMID 28718903 Get It

Cardiovascular disease represents the single largest contributor to morbidity and mortality, yet the flow of therapeutic innovation is lagging. Globally, academia, industry, and regulatory agencies must work together to address this gap, and ensure new disruptive therapeutic modalities to address growing needs of patients and society.
Long‐term analysis of phase II studies of single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma
Witzig, Thomas E. , Zinzani, Pier Luigi , Tuscano, Joseph M. , Drach, Johannes, Ramchandren, Radhakrishnan , Beşışık, Sevgi Kalayoğlu , Takeshita, Kenichi , Bravo, Marie‐Laure Casadebaig, Zhang, Lei , Witzig, T.E. , Habermann, Thomas M. , Fu, Tommy , Goy, Andre Henri , Zinzani, Pier Luigi

Mayo Clinic

American Journal of Hematology | July 12, 2017 | Volume: 92 | Issue: 10 | Pages: No page available

10.1002/ajh.24854 | PMID 28699256 Get It

AbstractMantle cell lymphoma (MCL) is a type of non‐Hodgkin lymphoma (NHL) with aggressive disease characteristics resulting in multiple relapses after initial treatment. Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on results from 3 multicenter phase II studies (2 including relapsed/refractory aggressive NHL and 1 focusing on MCL post‐bortezomib). The purpose of this report is to provide longer follow‐up on the MCL‐001 study (follow‐ups were 6.8 [NHL‐002], 7.6 [NHL‐003], and 52.2 [MCL‐001] months). The 206 relapsed MCL patients treated with single‐agent lenalidomide (25 mg/day PO, days 1 to 21 every 28‐days) had a median age of 67 years (63% ≥65 years), 91% with stage III/IV disease, and 50% with ≥4 previous treatment regimens. With a median follow‐up of X, the combined best overall response rate (ORR) was 33% (including 11% with complete remission [CR]/CR unconfirmed CRu). Lenalidomide produced rapid and durable responses with a median time to response of 2.2 months and median duration of response (DOR) of 16.6 months (95% CI: 11.1%‐29.8%). The safety profile was consistent and manageable; myelosuppression was the most common adverse event (AE). Overall, single‐agent lenalidomide showed consistent efficacy and safety in multiple phase II studies of heavily pretreated patients with relapsed/refractory MCL, including those previously treated with bortezomib.